Commonwealth Serum Laboratories (CSL), an Australian biotechnology company and the world’s second-biggest flu vaccine manufacturer, has agreed to pay $312 million ($US200 million) to use groundbreaking mRNA vaccine technology from a U.S. company.
The vaccine manufacturer announced on Nov. 2 that it had licenced the new technology with Arcturus Therapeutics, an American mRNA medicines biotechnology company.
“This collaboration is an exciting opportunity to complement CSL’s own next-generation mRNA program with a partner who developed a platform to deliver late-stage clinical supplies at scale,” CSL Chief Operating Officer Paul McKenzie said in a statement.
“These combined capabilities will accelerate our journey in mRNA.”…